Prognostic Evaluation of Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score and Hematological Indices in Classic Hodgkin Lymphoma

ABSTRACT Introduction Hodgkin lymphoma (HL) constitutes 10% of all lymphoma diagnoses and accounts for 5% of lymphoma‐related deaths. Accurate prognostication in HL remains crucial, particularly given that 10%–20% of patients may receive either insufficient or excessive treatment. This study investigates the effect of hemoglobin, albumin, lymphocyte, and platelet (HALP) score, which is a marker of inflammation status and nutrition, at the time of diagnosis for the patients with HL on prognosis. Materials and Methods A total of 147 patients diagnosed with cHL were included in the study, and their data were analyzed retrospectively. The significance of the HALP score and hematological indices [neutrophil‐lymphocyte ratio (NLR), lymphocyte‐monocyte ratio (LMR), and platelet‐lymphocyte ratio (PLR)] as predictors of overall survival (OS) and disease‐free survival (DFS) was evaluated. Results Patients were grouped according to median values for the HALP score and hematological indices. High HALP score ( p = 0.034), low NLR ( p = 0.033), high LMR ( p = 0.003), and low PLR ( p = 0.014) were statistically significant in the early‐stage favorable group. DFS and OS were not statistically significant according to the HALP score NLR, LMR, and PLR groups. Conclusion The need for readily applicable, reliable prognostic markers in cHL, where immunotherapy treatments have led to significantly improved survival outcomes, remains persistent.